List view / Grid view
5 February 2016 | By Victoria White
New research suggests that drugs to prevent, rather than encourage, cell death might be effective at fighting cancer - contrary to how many of the current chemotherapy drugs work...
3 February 2016 | By Victoria White
XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumours, including breast, gastric and non-small cell lung cancers...
3 February 2016 | By Victoria White
A new ‘roadmap’ document published today outlines how The London Cancer Hub will become a world-leading life-science campus...
3 February 2016 | By Victoria White
The enhanced agreement will accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1...
2 February 2016 | By Victoria White
The £60 million enables the company to maximise the potential of its DUB platform and advance a series of DUB inhibitors...
29 January 2016 | By Victoria White
Researchers have identified the cells that likely give rise to the brain tumour subtype Group 4 medulloblastoma, removing a barrier to developing more effective targeted therapies....
29 January 2016 | By SMi Group
Registration now live for the 5th annual ADC Summit taking place at the Holiday Inn Kensington Forum, London, UK on the 23rd – 24th May 2016...
29 January 2016 | By Victoria White
The lab headed by Thomas Helleday at Karolinska Institutet and Biovica are to collaborate to improve evaluation of new, promising cancer therapies...
28 January 2016 | By Victoria White, Digital Content Producer, Drug Target Review
2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
27 January 2016 | By Victoria White
Myeloma UK and the SGC have entered into an open-access research partnership to discover drug targets for myeloma using structural biology and chemical proteomics...
26 January 2016 | By Victoria White
Scientists from UTSW have crafted synthetic "dendrimer" nanoparticles that are able to provide a tumour-suppressing effect without further damaging the liver or neighbouring tissue...
26 January 2016 | By Victoria White
Researchers say the fabrication technique could slash 90% of the cost of mass-producing metastatic microtumours and therapeutic microtissues for screening and research...
26 January 2016 | By Victoria White
During trials of ABTL0812, researchers identified a new mechanism of action: the activation of the PPAR receptors and the TRIB3 gene, leading to inhibition of the Akt/mTOR pathway...
22 January 2016 | By Victoria White
The research from Georgia State University scientists provides strong translational potential with respect to biomarkers that play critical roles in the development of endometrial/lung tumours...
